What's Hot

    Wall Street searches for path forward of Big Tech earnings and Fed assembly | Invesloan.com

    April 27, 2026

    NYC Mayor Mamdani vetoes NYPD protest plan invoice citing free speech considerations | Invesloan.com

    April 27, 2026

    Inside USS Torsk, Last US Submarine to Sink Enemy Ship Until Iran War | Invesloan.com

    April 27, 2026
    Facebook Twitter Instagram
    Finance Pro
    Facebook Twitter Instagram
    invesloan.cominvesloan.com
    Subscribe for Alerts
    • Home
    • News
    • Politics
    • Money
    • Personal Finance
    • Business
    • Economy
    • Investing
    • Markets
      • Stocks
      • Futures & Commodities
      • Crypto
      • Forex
    • Technology
    invesloan.cominvesloan.com
    Home » Woman Pays for Semaglutide by Working Two Jobs After Regaining Weight | Invesloan.com
    Money

    Woman Pays for Semaglutide by Working Two Jobs After Regaining Weight | Invesloan.com

    January 22, 2025Updated:January 22, 2025
    Share
    Facebook Twitter LinkedIn Pinterest Email
    • Staci Rice lost 64 pounds on a compounded form of the weight loss drug semaglutide.
    • It was expensive so she tried to maintain her weight loss without the medication, and gained 26 pounds.
    • Rice started a side hustle so she could go back on the medication.

    The weight loss drug semaglutide was a “miracle” for Staci Rice, making cravings and “food noise” disappear and helping her to lose 64 pounds in around eight months.

    To afford to keep taking the drug, she started a side-hustle in digital marketing alongside the 40-hours a week she worked to get her new insurance business off the ground.

    Semaglutide, marketed as Wegovy for weight loss and Ozempic for diabetes, is part of the family of appetite-suppressing drugs called GLP-1s, which includes products such as Mounjaro. Many insurance companies cover the drugs for diabetes but not weight loss.

    Rice, 42, from Georgia, is among users who take compounded GLP-1s that aren’t FDA-approved, because they are significantly cheaper than branded products that can cost around $1,000 a month.

    In August 2024, Eli Lilly reduced the price of its GLP-1 Zepbound by almost 50% to compete with knock-offs. It now sells for $399 to $549 a month, down from $1,059. In November, the Biden administration proposed a new rule to expand Medicare and Medicaid coverage to include GLP-1s for weight loss, but it’s unclear if President Donald Trump will follow through.

    But even the compounded form, which cost Rice $499 at the time, was expensive.

    Rice stopped using semaglutide and gained 20 pounds

    Rice started taking weekly injections of semaglutide in May 2022. After she achieved her goal of losing 64 pounds, she saved up for a $18,500 “mommy makeover” (tummy tuck and breast augmentation) in April 2023, she told Business Insider.

    Related stories

    GLP-1 users are encouraged to build up from a low dose to minimize side effects like nausea and constipation. At first, a $499 supply lasted Rice three months, reducing to a month as she upped the dose.

    After the surgery, she started injecting the medication less frequently to maintain her weight rather than lose more. In early 2024, money was tight after Rice changed jobs and semaglutide seemed like something she could cut back on. She bought the compounded drug online, so she made these changes without the guidance of a medical professional.

    Dr. Spencer Nadolsky, an obesity specialist and founder of a virtual health clinic specializing in GLP-1s, told BI that it’s not advisable to change doses without consulting a doctor.

    “I thought that I could go less and less, and eventually, I got to where I was forgetting to take the injection,” Rice said. “I was thinking I had this, I was thinking, ‘Now I’m set. I don’t need to take the medicine anymore.'”


    A composite image of Staci Rice

    Staci Rice in June 2023 after her ‘mommy makeover’ (left) and in November 2024.

    Staci Rice



    Rice maintained her weight for a couple of months. And although she started eating more, she presumed it wouldn’t affect her progress.

    But the “food noise” in Rice’s head — cravings for sugar and sweet treats when experiencing heightened emotions — gradually returned, and she regained 26 pounds over about six months.

    Rice had a small amount of medication left which she would take now and then, but it wasn’t enough to lose weight, and she couldn’t afford her previous maintenance dose.

    “I started to notice my clothes were getting tighter,” Rice said. Knee problems, a swollen finger, and various other aches and pains returned.

    Nadolsky said he’d seen clients who abruptly stopped taking GLP-1s because their insurance no longer covered them or there were shortages. However, regaining weight is the biggest risk associated with coming on and off the medicine, he said.

    “Obesity is a chronic disease and these medicines work by helping people manage their appetite and food noise,” he said. “The cost of these medicines must come down. And if insurance doesn’t cover them, it would be ideal that the cost would be low enough to pay out-of-pocket for them. The medicines are not a short-term fix. They are designed and used for the chronic disease of obesity.”

    Lars Fruergaard Jørgensen, the CEO of Novo Nordisk which makes Ozempic and Wegovy, has previously blamed insurers and middlemen for the high prices of the drugs.

    A side hustle to fund semaglutide

    Towards the end of 2024, Rice had started her side hustle and restarted the medication on a low dose to minimize costs, deciding when to start and stop without medical guidance. The cost was different depending on the provider, and she used the money from her “very stressful” jobs to pay for it.

    She now takes a low weekly dose (0.25 milligrams was her lowest, and her highest 2.5 milligrams). A 10-week supply costs her $305, and she is budgeting to afford it.

    “I’m going to get back on track and I’m going to get back to where I was,” Rice said. “But I hate that I ended up spending a good amount on a mommy makeover.”

    Rice said she feels guilty that she put her family in a financial bind and, if she could go back in time, isn’t sure she would have had the surgery.

    She hopes she’ll be back at her goal weight by February, and then plans to stay on a maintenance dose long-term. She sees regaining the weight as a valuable lesson that maintainance without medication isn’t as easy as she thought.

    “It is a miracle medicine,” Rice said. “I’m always going to be an advocate for it.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Keep Reading

    Inside USS Torsk, Last US Submarine to Sink Enemy Ship Until Iran War | Invesloan.com

    This $500 Shoe Is About to Take Over Your Running Club Convos | Invesloan.com

    My Father Still Works at 87, and I’m 62 With No Plans to Retire | Invesloan.com

    Are we ‘tokenmaxxing’ too near the solar? | Invesloan.com

    How Disney Tech Employees Are Using AI, by the Numbers | Invesloan.com

    For Young Founders, Selfie Sticks Are As Vital As Funding | Invesloan.com

    Russia Hits Shortage for Antidrone Air Defense Missiles, Ukraine Says | Invesloan.com

    Maria Sharapova, 39, Says Her Intensity Was Key to Her Success | Invesloan.com

    Sydney Sweeney’s Business Strategy: a Blank Canvas for Roles and Brand Deals | Invesloan.com

    LATEST NEWS

    Wall Street searches for path forward of Big Tech earnings and Fed assembly | Invesloan.com

    April 27, 2026

    NYC Mayor Mamdani vetoes NYPD protest plan invoice citing free speech considerations | Invesloan.com

    April 27, 2026

    Inside USS Torsk, Last US Submarine to Sink Enemy Ship Until Iran War | Invesloan.com

    April 27, 2026

    Global oil costs high $100 a barrel once more after U.S.-Iran peace talks canceled — however Tehran presents deal to reopen Strait of Hormuz | Invesloan.com

    April 27, 2026
    POPULAR

    China’s first passenger jet completes maiden commercial flight

    May 28, 2023

    Numbers taking US accountancy exams drop to lowest level in 17 years

    May 29, 2023

    Toyota chair faces removal vote over governance issues

    May 29, 2023
    Advertisement
    Load WordPress Sites in as fast as 37ms!
    Facebook Twitter Pinterest WhatsApp Instagram
    © 2007-2023 Invesloan.com All Rights Reserved.
    • Privacy
    • Terms
    • Press Release
    • Advertise
    • Contact

    Type above and press Enter to search. Press Esc to cancel.

    invesloan.com
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}